default author photo

Michael Frumovitz

University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine

1515 Holocombe Blvd

Houston, TX 77030

United States

SCHOLARLY PAPERS

2

DOWNLOADS

340

TOTAL CITATIONS

3

Scholarly Papers (2)

1.

The Gut and Cervical Microbiome Promote Immune Activation and Response to Chemoradiation in Cervical Cancer

Number of pages: 49 Posted: 20 Jun 2018
University of Texas at Houston - Department of Radiation Oncology, University of Texas at Houston - Department of Radiation Oncology, University of Texas at Houston - Department of Radiation Oncology, University of Texas at Houston - Department of Radiation Oncology, University of Texas at Houston - Department of Surgical Oncology, University of Texas at Houston - Department of Surgical Oncology, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, University of Texas at Houston - Department of Radiation Oncology, University of Texas at Houston - Department of Radiation Oncology, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, Louisiana State University, Baton Rouge - School of Medicine, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, University of Texas at Houston - Department of Radiation Oncology, University of Texas at Houston - Department of Immunology, University of Texas at Houston - Department of Immunology, University of Texas at Houston - Department of Diagnostic Radiology, Baylor University - The Alkek Center for Metagenomics and Microbiome Research, Baylor University - The Alkek Center for Metagenomics and Microbiome Research, University of Texas at Houston - Department of Radiation Oncology, University of Texas at Houston - Department of Radiation Oncology, University of Texas at Houston - Center for Infectious Diseases, Baylor University - The Alkek Center for Metagenomics and Microbiome Research, University of Texas at Houston - Department of Genomic Medicine, University of Texas at Houston - Department of Radiation Oncology and University of Texas at Houston - Department of Radiation Oncology
Downloads 188 (403,391)
Citation 3

Abstract:

Loading...

2.

Efficacy of Pembrolizumab in Patients with Advanced Rare Cancers

Number of pages: 41 Posted: 31 May 2019
University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - Investigational Cancer Therapeutics, Baylor College of Medicine, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston, Health Science Center at Houston (UTHealth), MD Anderson Cancer Center, Department of Radiology, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Department of Thoracic/Head and Neck Medical Oncology, University of Texas at Houston - Department of Genitourinary Medical Oncology, University of Texas at Houston - Department of Genitourinary Medical Oncology, University of Texas at Houston - Department of Genomic Medicine, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Department of Translational Molecular Pathology, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, University of Texas at Houston - Department of Genitourinary Medical Oncology, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas Rio Grande Valley (UTRGV) (Formerly University of Texas-Pan American), University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - Investigational Cancer Therapeutics, R Simon Consulting, University of Texas at Houston - Department of Biostatistics, University of Texas at Houston - MD Anderson Cancer Center and University of Texas at Houston - MD Anderson Cancer Center
Downloads 152 (488,442)

Abstract:

Loading...